ak146d1
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 2, 2025 (NCT06929663)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TACSTD2 inhibitor
- Nectin-4INHIBITOR
NECTIN4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07067567 | Phase 1 | Aug 7, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06929663 | Phase 1 | Jul 2, 2025 | Akeso Pharmaceuticals, Inc., Austin Health |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2025 |
| Austin Health | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1